Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00105937 · ClinicalTrials.gov registry record · Phase 3
OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
A Phase 3 study, sponsored by Cephalon.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT00105937 is a Phase 3 study that has completed, run by Cephalon. The registered enrollment target is 300 participants.
The verdict
NCT00105937, a Phase 3 study, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety and efficacy of OraVescent fentanyl to treat breakthrough pain episodes in cancer patients who are already opioid tolerant.
Interventions
- DRUG OraVescent fentanyl citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2004-04 |
| Est. Completion | 2006-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00105937
The ClinicalTrials.gov registry entry for NCT00105937 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OraVescent fentanyl citrate is the first listed.
NCT00105937 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00105937 about?
NCT00105937 is a clinical study titled "OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients". The purpose of this study is to evaluate the long-term safety and efficacy of OraVescent fentanyl to treat breakthrough pain episodes in cancer patients who are already opioid tolerant.
What is the current status of trial NCT00105937?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2004-04. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00105937?
The interventions under investigation include: OraVescent fentanyl citrate (DRUG).
Who is sponsoring clinical trial NCT00105937?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.